A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells

Assay and Drug Development Technologies

Volumn 12, Issue 1, 2014, Pages 28-42

  Antczak, Christophe ^a   Wee, Boyoung ^a   Radu, Constantin ^a   Bhinder, Bhavneet ^a   Holland, Eric C ^a   Djaballah, Hakim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2 PHENYLMELATONIN; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ABAMECTIN; ACACETIN; ALTANSERIN; AMINOPURVALANOL A; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; APIGENIN; BREAST CANCER RESISTANCE PROTEIN; BROMOCRIPTINE MESILATE; DIPYRIDAMOLE; DOXAZOSIN MESYLATE; FIDUXOSIN; IMATINIB; ISOLIQUIRITIGENIN; IVERMECTIN; LAPATINIB; LASALOCID; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NSC 625987; PROTEIN INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB; ZIPRASIDONE;

ARTICLE; AUTOFLUORESCENCE; CANCER CELL CULTURE; CELL DENSITY; CELL MEMBRANE; CELL MIGRATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; FLOW CYTOMETRY; GENE ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; REPRODUCIBILITY; SIGNAL NOISE RATIO;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASM PROTEINS;

EID: 84896728195     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.521     Document Type: Article

References (42)

1. Loscher W, Potschka H: Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
2. Robey RW, Polgar O, Deeken J, To KW, Bates SE: ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26:39-57.
3. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806.
4. Bleau AM, Huse JT, Holland EC: The ABCG2 resistance network of glioblastoma. Cell Cycle 2009;8:2936-2944.
5. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF: Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010;334: 147-155.
6. Carcaboso AM, Elmeliegy MA, Shen J, et al.: Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010;70: 4499-4508.
7. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y: Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 2008;36:995-1002.
8. Henrich CJ, Bokesch HR, Dean M, et al.: A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11:176-183.
9. Ivnitski-Steele I, Larson RS, Lovato DM, et al.: High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol 2008;6:263-276.
10. Robey RW, Honjo Y, van de Laar A, et al.: A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512:171-182.
11. Saito H, Hirano H, Ishikawa T: High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini Rev Med Chem 2007;7:1009-1018.
12. Strouse JJ, Ivnitski-Steele I, Khawaja HM, et al.: A selective ATP-binding cassette subfamily g member 2 efflux inhibitor revealed via high-throughput flow cytometry. J Biomol Screen 2013;18:26-38.
13. Muenster U, Grieshop B, Ickenroth K, Gnoth MJ: Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 2008;25:2320-2326.
14. Zhang Y, Byun Y, Ren YR, et al.: Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res 2009;69: 5867-5875.
15. Glavinas H, Kis E, Pal A, et al.: ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab Dispos 2007;35:1533-1542.
16. Pick A, Klinkhammer W, Wiese M: Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem 2010;5:1498-1505.
17. Molina JR, Kaufmann SH, Reid JM, et al.: Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14:7900-7908.
18. Lemos C, Kathmann I, Giovannetti E, et al.: Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 2008;123:1712-1720.
19. Antczak C, Mahida JP, Bhinder B, Calder PA, Djaballah H: A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. J Biomol Screen 2012;17: 885-899.
20. Bleau AM, Hambardzumyan D, Ozawa T, et al.: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226-235.
21. Zhang Y, Gupta A, Wang H, et al.: BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 2005;22:2023-2034.
22. Gonzalez-Lobato L, Real R, Prieto JG, Alvarez AI, Merino G: Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol 2010;644:41-48.
23. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50.
24. Lepist EI, Phan TK, Roy A, et al.: Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012;56:5409-5413.
25. Lee G, Ramirez CN, Kim H, et al.: Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012;30:1244-1248.
26. Vannini I, Zoli W, Fabbri F, et al.: Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anticancer Drugs 2009;20:918-925.
27. Nakanishi T, Shiozawa K, Hassel BA, Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108:678-684.
28. Katayama K, Masuyama K, Yoshioka S, et al.: Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 2007;60:789-797.
29. Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-1216.
30. Vautier S, Milane A, Fernandez C, et al.: Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci 2009;12:199-208.
31. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P: Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009;26:1816-1831.
32. Mo W, Zhang JT: Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012;3:1-27.
33. Zhang S, Wang X, Sagawa K, Morris ME: Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos 2005;33:341-348.
34. Bisi A, Meli M, Gobbi S, et al.: Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives. Bioorg Med Chem 2008;16: 6474-6482.
35. Wesolowska O, Molnar J, Ocsovszki I, Michalak K: Differential effect of phenothiazines on MRP1 and P-glycoprotein activity. In Vivo 2009;23:943-947.
36. Pick A, Wiese M: Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMed Chem 2012;7:650-662.
37. Xiong N, Long X, Xiong J, et al.: Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Crit Rev Toxicol 2012;42:613-632.
38. Lee YB, Ko KC, Shi MD, et al.: a-Mangostin, a novel dietary xanthone, suppresses TPA-mediated MMP-2 and MMP-9 expressions through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells. J Food Sci 2010;75:H13-H23.
39. Brimacombe KR, Hall MD, Auld DS, et al.: A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol 2009;7:233-249.
40. Duan Z, Choy E, Hornicek FJ: NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009;4:e7415.
41. Mogi M, Yang J, Lambert JF, et al.: Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003;278:39068-39075.
42. Imai Y, Ohmori K, Yasuda S, et al.: Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase. Cancer Sci 2009;100:1118-1127.